作者
Didier Meulendijks, Linda M Henricks, Gabe S Sonke, Maarten J Deenen, Tanja K Froehlich, Ursula Amstutz, Carlo R Largiadèr, Barbara A Jennings, Anthony M Marinaki, Jeremy D Sanderson, Zdenek Kleibl, Petra Kleiblova, Matthias Schwab, Ulrich M Zanger, Claire Palles, Ian Tomlinson, Eva Gross, André BP Van Kuilenburg, Cornelis JA Punt, Miriam Koopman, Jos H Beijnen, Annemieke Cats, Jan HM Schellens
发表日期
2015/12/1
来源
The Lancet Oncology
卷号
16
期号
16
页码范围
1639-1650
出版商
Elsevier
简介
Background
The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the gene encoding DPD (DPYD), including DPYD*2A and c.2846A>T. Three other variants—DPYD c.1679T>G, c.1236G>A/HapB3, and c.1601G>A—have been associated with DPD deficiency, but no definitive evidence for the clinical validity of these variants is available. The primary objective of this systematic review and meta-analysis was to assess the clinical validity of c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity.
Methods
We did a systematic review of the literature published before Dec 17, 2014, to identify cohort studies investigating associations between DPYD c.1679T>G, c.1236G>A/HapB3, and c.1601G>A and severe (grade ≥3) fluoropyrimidine-associated toxicity in …
学术搜索中的文章
D Meulendijks, LM Henricks, GS Sonke, MJ Deenen… - The Lancet Oncology, 2015
